Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Five successful poster presentations at ESMO in Berlin

We are delighted that five EUMelaReg projects had been selected to be presented at this years ESMO congress in Berlin. A special thank you to all the collaborators. Here is a short overview of our projects:

Clinical outcomes in patients with melanoma brain metastases: 1st line treatment options

The EMR Working Group "BrainMets" evaluated patients with melanoma brain metastasis who received 1L treatment. Symptomatic patients were defined as those requiring corticosteroids at the initiation of 1L treatment. Primary endpoints were OS and melanoma-specific survival. Secondary endpoints included PFS, response rates and stratified analyses for BRAF mutational status and various prognostic factors. In summary, symptomatic patients with melanoma brain metastasis show markedly inferior survival. Despite lower ORR and shorter PFS, symptomatic patients treated with ipilimumab/nivolumab had notably longer OS than those treated with BRAF/MEKi, supporting the use of 1L immunotherapy even in this high-risk group.

Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure. A EUMelaReg real-world study.

This study evaluated patients from the EUMelaReg registry diagnosed with BRAFV600 metastatic melanoma who received BRAF/MEKi in 2L after failure of 1L ICI versus those who received BRAF/MEKi in 1L. Key outcomes focused on OS, PFS, ORR, and TOT. In summary, the use of BRAF/MEKi in the 2L after ICI failure does not compromise key outcomes, affirming the clinical benefit in this sequencing approach for BRAFV600 mutated melanoma. The results provide additional support for a preferred sequencing of 1L ICI and 2L BRAF/MEKi for these patients.

The role of BRAF/MEKi rechallenge in BRAFV600 mutated melanoma patients. Insights from a EUMelaReg real-world study.

This study evaluated patients from the EUMelaReg registry with BRAFV600 metastatic melanoma who were rechallenged with BRAF/MEKi after failing from ICI following prior treatment with either adjuvant or non-adjuvant BRAF/MEKi. Sensitivity analyses compared rechallenged patients with BRAF/MEKi-naive patients. Objectives focused on ORR, PFS, and OS from start of rechallenge BRAF/MEKi.

In summary, rechallenge with BRAF/MEKi lead to clinically meaningful benefit in terms of ORR and survival outcomes in patients who already received an initial BRAF/MEKi therapy for advanced disease, or as an adjuvant pre-treatment. Rechallenging patients with BRAF/MEKi therapy represent a viable treatment option for patients who have failed on immunotherapy.

Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma. A EUMelaReg real-world study.

This study evaluated patients from the EUMelaReg registry with BRAFV600 metastatic melanoma who achieved tumor control (CR/PR/SD) from 1L BRAF/MEKi and either received ICI in 2L or no 2L therapy. We compared those who switched to 2L ICI without having progressed to the remaining cohort. The main outcome was OS from 1L treatment. As secondary outcomes, 2L ICI was evaluated for response rates and PFS.

In summary, after achieving tumor control from BRAF/MEKi, switching to ICI might improve clinical outcomes including OS. This could be considered in the current guideline recommendations in 1L for patients who are not suitable for ICI upfront.

Treatment patterns using encorafenib plus binimetinib in patients with BRAF mutated melanoma

This study evaluated patients from the EUMelaReg registry with metastatic melanoma, who received encorafenib/binimetinib between Sep 2018 and Jan 2024. Patients were stratified into groups based on the line of treatment, and the class of preceding systemic treatments. Patterns of encorafenib/binimetinib treatment were the main focus of the analysis.

In summary, this study informs on patient profiles and related outcome variables and shows efficacy for different treatment settings and lines.